Assyro AI

FDA Orange Book · active-ingredient family

Chlordiazepoxide hydrochloride; clidinium bromide

Chlordiazepoxide hydrochloride; clidinium bromide is approved as 1 brand and 13 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:LIBRAX · NDA 012750

1

Brand (NDA)

13

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule

ProductApplicantApplicationTEApproved
LIBRAXRLDBAUSCHNDA 012750ABApproved Prior to Jan 1, 1982

Generic (ANDA) products (13)

ProductApplicantApplicationTEApproved
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEWINDER LABS LLCANDA 212344ABJul 08, 2024
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDETORRENTANDA 217385Dec 14, 2023
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEALEMBICANDA 216969ABSep 15, 2023
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEAUROBINDO PHARMA LTDANDA 216419ABSep 14, 2023
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDECOREPHARMAANDA 215453ABJul 29, 2022
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEMICRO LABSANDA 215835ABJul 19, 2022
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDETEVA PHARMS USAANDA 211476Nov 02, 2021
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEAMNEALANDA 215555ABOct 25, 2021
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEDR REDDYSANDA 214698ABMay 10, 2021
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEALKEM LABS LTDANDA 214065ABApr 26, 2021
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDECHARTWELL RXANDA 213530ABOct 20, 2020
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDEMISEMERANDA 210579ABJul 29, 2020
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDENUVO PHARMS INCANDA 211421ABJul 07, 2020

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Chlordiazepoxide hydrochloride; clidinium bromide — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.